Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Alzheimer's
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Alzheimer's
    Ginkgo biloba for Prevention of Dementia: A Randomized Controlled Trial - (JAMA)
    Rapid Screening Test to Detect Early Alzheimer's Disease Proves Effective - (DGNews)
    MK-677 Does Not Slow Rate of Alzheimer's Disease Progression - (DGNews)
    Brain Scans Demonstrate Link Between Education, Alzheimer's Disease Symptoms - (DGNews)
    TopAbstracts in Alzheimer's 11/13/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Alzheimer's
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Modifiable Risk Factors Underlie Higher Dementia Rates in African Americans
    • Creativity and Dementia: Emerging Diagnostic and Treatment Methods for Alzheimer's Disease
      Next Steps in Alzheimer's Disease: Improvements in Diagnosis and Treatment
      New Perspectives on Common Clinical Conditions

      Webcasts/CME archive

       Recent cases - Alzheimer's
        Rapid Cognitive Improvement in Alzheimer's Disease Following Perispinal Etanercept Administration
        Advances in the Pharmacotherapy of Alzheimer's Disease
        Distinguishing Alzheimer's From Parkinson's
        Does He Have Alzheimer's Disease?

        Cases archive
          




        my personal edition > alzheimer's > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Long-term Benefits of Galantamine Treatment for Patients with Vascular Dementia or Alzheimer's disease

        A DGReview of :"Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease"
        CNS Drugs

        09/23/2003
        By Keely S. Solomon PhD


        Galantamine therapy given for a longer period, and/or initiated earlier, may provide an increase in cognitive benefits for patients with Alzheimer's disease, say researchers.

        Galantamine, an acetylcholinesterase inhibitor, has been shown in a 6-month study to provide cognitive benefits for patients with vascular dementia or Alzheimer's disease with cerebrovascular disease (Alz/cer). A study extension demonstrated that patients receiving galantamine for 12 months may benefit from long-term treatment.

        Gary Small, MD, with the University of California, Los Angeles, United States, and colleagues performed a sub-analysis of the trial data to determine if long-term efficacy of galantamine is influenced by dementia type (vascular versus Alz/cer).

        In the original study, patients (aged 40 to 90) were randomised to receive galantamine 24 mg/day (n=396) or placebo (n=196) for 6 months. Those who completed the trial were then eligible to enter a 6-month open-label phase during which all patients received galantamine 24 mg/day. Cognitive efficacy was assessed as changes in score on the 11-item Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog/11).

        Patients with vascular dementia who received galantamine for the entire 12-month period showed significant improvement in cognition scores at study end compared with baseline (mean change, -2.1 ± 0.74). Although these patients had a 4-fold greater improvement at 6 months compared with those who received placebo, the placebo group showed a similar improvement in cognitive function after receiving galantamine for the 6-month extension period.

        Alz/cer patients who received galantamine continuously for 12 months maintained baseline cognitive scores at the end of the study period Those who were switched from placebo to galantamine at month 6 showed a significant improvement by month 12, but the cognition level was significantly lower than for those who received galantamine for the entire study period.

        "Our study provides evidence that patients with these common subtypes of dementia may benefit from galantamine therapy that is maintained for at least 1 year," the researchers conclude.



        CNS Drugs 2003;17:12:905-14. "Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send